Concord Biotech Ltd

- As of the latest update in February 2025, Concord Biotech has indicated that CapEx is largely complete, particularly for the injectable unit with INR 225 crores spent, which will be capitalized. - For FY '25, there is no expectation of growth CapEx; only maintenance CapEx around INR 15-20 crores per annum is planned. - The company mentioned that if new opportunities arise in fermentation or adjacent areas, they may consider in-house or external investments, but no specific plans for new fundraising through debt or equity were disclosed. - Overall, there is no explicit mention of any current or imminent fundraising via debt or equity in the provided material.

- Capex for FY '24-'25 is largely complete, with INR 225 crores spent on the injectable unit to be capitalized. - No significant growth capex expected for FY '24-'25; only maintenance capex of around INR 15-20 crores per annum anticipated. - Future capex may be considered if new opportunities arise within or adjacent to fermentation APIs, either in-house or through procurement. - Strategic investment: Concord will acquire a 26% equity stake in CleanMax Private Limited and CleanMax Enviro Energy Solutions (renewable energy provider in Gujarat). - This investment supports sustainability goals by powering the Dholka plant with 6.6 MW wind and 3.3 MW DC solar capacity, reducing carbon footprint and energy costs. - Injectable plant is scheduled to begin commercial production this quarter, with expected ramp-up and contribution to revenue and profitability in the coming years.

- Concord Biotech targets a 20% to 25% CAGR growth in overall sales/revenue over the next 3 to 5 years. - Growth is expected from both API and formulation segments, with API contributing around 80% and formulations about 20%. - API third-party sales are anticipated to grow at around 10-12%, while formulations, especially due to capacity ramp-up, are expected to grow north of 40% to achieve overall 20%+ company growth. - Injectables are expected to gradually contribute more, with asset turnovers of INR 300-600 crores and a phased ramp-up over 5 years contributing about 6% growth. - Growth is volume-driven with stable pricing; no significant price hikes anticipated. - Capacity utilization at key units (Unit 1: 78%, Unit 3: 35%) is expected to increase, supporting growth. - Growth opportunities exist in fermentation APIs and CDMO space, including peptides, but these are in early stages.

- Concord Biotech targets a 20% to 25% CAGR growth in sales over the next 3 to 5 years at the company level. - API sales (third-party) are expected to grow at about 10% to 12%, reflecting its mature status. - Formulation sales are anticipated to grow over 40%, driven by capacity ramp-ups and new injectable product contributions. - EBITDA margins are projected to remain stable in the 40%-43% range, with potential upside as injectable facilities ramp up. - Profit after tax growth tracked 9% Y-o-Y for the 9 months ended Dec 2024; with the expected sales growth, PAT should improve accordingly. - Growth will be volume-driven, with stable pricing and limited significant price hikes. - The journey to 25% CAGR may be stepwise, with stronger growth expected in FY '26 and beyond as injectables and formulations contribute more. - CapEx for FY '25 and FY '26 will be minimal, focusing on maintaining current capacities. Overall, Concord expects improving earnings driven by formulation ramp-up and steady API growth.

- Concord Biotech has a strong order book position as of Q3 FY '25. - Certain opportunities are currently active and anticipated to convert within the quarter. - Some customer orders faced delays, pushing certain order executions from Q3 to Q4. - There is a possibility, though less likely, that some orders may move beyond Q4 into Q1. - The company remains confident in execution based on January and February performance. - Management is actively working on new customer acquisitions and expanding market share. - No specific numeric order book value disclosed, but execution visibility is positive with ongoing momentum.